Company

Oryzon Genomics SA

Madrid-based Oryzon Genomics SA develops epigenetic therapies for oncology and neurodegenerative diseases.

About

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company based in Madrid, Spain, founded in 2000 by Chairmen Carlos Buesa. It develops epigenetics-based therapies for cancer and neurodegenerative diseases, with two drugs in Phase II development: iadademstat (ORY-1001) and vafidemstat (ORY-2001). In November 2023 it raised venture funding from Nice & Green SA, and the company is listed at the Late stage.

3Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in